FDA Grants Orphan Drug Designation to March Biosciences for T-Cell Lymphoma
By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T cell therapy, which has shown promising safety and efficacy in Phase 1 trials, with a 44% response rate in TCL patients,...